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Disease Progression
Is as Important as
Culprit Lesion Treatment*
Antonio Colombo, MD, Azeem Latib, MD
Milan, Italy
Percutaneous revascularization for coronary artery disease
(CAD) aims to treat ischemia-producing lesions with a focus
on eliminating their negative impact. However, coronary ath-
erosclerosis is a generalized and progressive disease. Treatment
of a culprit stenosis may not alter the natural history of CAD
in which nonobstructive and non–ischemia-producing lesions
can progress to high-grade stenoses (1). In addition, a lack of
linical data documenting the long-term impact of disease
rogression after successful contemporary revascularization has
esulted in an underestimation of its contribution to future
dverse events. Indeed, one of the most difficult questions that
atients and referring physicians could ask us is: Will future
dverse events arise from the vessel revascularized or from
rogression of atherosclerotic disease in another coronary vessel
r in other segments of the treated artery? In this context, the
ndings of the BASKET-PRO (Basel Stent Kosten-
ffektivitäts Trial–PROgression of CAD) study in this issue of
he Journal are enlightening (2), as it provides important
information regarding the contribution of remote disease
progression, not only on late clinical events but also on new
symptomatic or silent ischemia.
See page 793
The investigators selected 428 patients from the BASKET
study (3) with successful and complete revascularization, de-
fined as the absence of clinical events or ischemic perfusion
defects at 6 months after intervention, and followed them for
5 years. Repeat single-photon emission computed tomography
(SPECT) scans were performed at 5 years on 206 patients
without late follow-up events who consented to a second
SPECT (35% did not). The main findings of this study were:
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contents of this paper to disclose.• Late clinical events occurred in 25.7% of patients, with
a 10% incidence of death and 8.4% of myocardial
infarction (MI) from 6 months to 5 years.
• Remote MI or revascularization accounted for 37.1%
of the late nonfatal events.
• Event rates were lower in remote versus target-vessel
areas (9.8% vs. 14.3%; p 0.019), mostly due to a lower
rate of MI in remote areas (1.9% vs. 6.3%; p  0.002).
• Patients with target-vessel events were more likely to
have both a revascularization and an MI than those
with remote events were (33.3% vs. 10.5%; p  0.01).
• New ischemic perfusion defects were detected in
23.3% and were silent in the majority (71%). Remote
ischemia accounted for 37.5% of new perfusion defects
in patients without events.
• No difference was detected in the frequency of remote
events or new perfusion defects between drug-eluting
and bare-metal stents.
We congratulate Zellweger et al. (2) for the very high rate of
linical follow-up (97%), including the large number of
PECT studies performed at 6 months and 5 years. A minor
imitation of the present study is that although the investigators
uantified the magnitude of events, they gave no information
bout the nature of these events, especially for the target vessel.
arget-vessel events may occur due to the target lesion (reste-
osis, stent thrombosis, or neoatherosclerosis) or due to prox-
mal or distal disease progression. Similarly, a proportion of the
ew target-vessel perfusion defects may indicate disease pro-
ression rather than stent failure. Thus, it is conceivable that
he proportion of late events and new perfusion defects due to
AD progression has been underestimated.
There are a limited number of studies documenting the
ong-term natural history of CAD progression after stenting
ith which to compare and validate these data. In a large
ercutaneous coronary intervention (PCI) registry of 3,474
atients, Glaser et al. (4) reported that 6% of initially noncul-
rit coronary lesions will have clinical plaque progression
equiring non–target-lesion PCI by 1 year. Cutlip et al. (5)
rovided longer-term data on 1,228 patients after implantation
f second-generation bare-metal stents. Stent-related events
redominated during the first year of follow-up (18.3% for
arget-lesion and 12.4% for non–target-lesion events), becom-
ng less common during years 2 to 5 (average annual hazard
ate: 1.7% and 6.3% for target- and non–target-lesion events,
espectively). Similarly, remote-vessel and target-vessel revas-
ularization occurred at similar rates between years 2 to 5
average annual hazard rate: 3.5% vs. 2.4%), but about one-half
f the target-vessel revascularizations were due to progression
f disease at nonstented sites rather than failure of the stent and
ts margins. In both studies, a larger CAD burden was
ssociated with a significantly higher risk for clinical plaque
rogression. In the contemporary drug-eluting stent era,
hacko et al. (6) and Leon et al. (7) reported 5-year data from
he SIRIUS (Sirolimus-Eluting Stent in De Novo Native
oronary Lesions) and the 4 TAXUS (Treatment of De Novo
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SIRIUS, non–target-vessel MI accounted for 28% and 17% of
all MI after sirolimus-eluting and bare-metal stent implanta-
tions (6). Although, the 5-year cumulative revascularization
incidence was 32.3% in the drug-eluting and 45.0% in the
bare-metal stent groups, target-lesion revascularization was
12.5% and 28.8%, respectively. This finding attests to the
importance of disease progression in remote coronary segments
as a significant source of future adverse events. Similarly, in the
pooled 5-year TAXUS data, approximately one-half of all late
Q-wave MIs occurred in nonstented vessels (thus completely
unrelated to the stent); and non–target-lesion revascularization
contributed equally with target-lesion revascularization to the
low ongoing rate of target-vessel revascularization after the first
year (7). However, no data are provided in this study about the
rates of remote-vessel revascularization. Finally, Alexopoulos et
al. (8) attempted to characterize the etiology of nonfatal acute
MI in 91 cases occurring 1 month after stent implantation
(32.6% drug-eluting stents). Myocardial infarction was attrib-
uted to disease progression at another site in 46.2%, restenosis
in 38.4%, and stent thrombosis in 11% of cases with a median
time from PCI to MI of 27, 19, and 9 months, respectively.
These 5 studies display a common thread. Disease progression
may be as important as stent failure and accounts for about
one-half of the adverse events during long-term follow-up.
However, we should not forget that the aforementioned
studies are limited by the inclusion of low-risk patients and lack
the high rate of clinical follow-up seen in the BASKET-PRO
study; some were retrospective; none were specifically designed
to study disease progression; and all focused only on patients
with events. The most distinctive feature of BASKET-PRO is
the performance of SPECT scans at 5 years in patients without
events in order to evaluate the magnitude and contribution of
clinically significant but “silent” CAD progression.
A question that the critical observer is forced to ask, is
whether surgical revascularization would have resulted in dif-
ferent outcomes, particularly as the majority of events were
related to the target vessel? Although coronary artery bypass
grafting (CABG) has no effect on disease progression in
nonbypassed vessels, Kroncke et al. (9) have elegantly demon-
trated that grafting a coronary artery increases the risk of
isease progression 3 to 6 times; predominantly resulting in
roximal (74%) rather than distal progression in arteries with
atent grafts; and the majority (78%) of progression in grafted
rteries was to 100% occlusion. Despite this negative effect on
isease progression, an arterial bypass graft may better protect
he coronary vessel by preventing future events from proximal
isease progression or plaque rupture. Indeed, the 4-year data
rom the SYNTAX (Synergy Between Percutaneous Coronary
ntervention With TAXUS and Cardiac Surgery) trial recently
resented by Patrick Serruys at the European Association of
ardiothoracic Surgery meeting in Lisbon should force us to
ake a moment of reflection. At 4 years, the rate of cardiac
eath and MI after revascularization in patients with multives-
el disease were significantly higher after PCI versus CABG
m
t7.6% vs. 4.3%, p  0.004, and 8.3% vs. 3.8%, p  0.001). A
difference in major adverse cardiovascular and cerebrovascular
event rates in favor of CABG was observed in patients with
intermediate (23 to 32) or high SYNTAX scores (33),
suggesting that CABG may be the standard of care in patients
with complex disease, whereas PCI may be acceptable in
patients with less complex disease, including the left main.
So what is the practical take-home message from this study?
In patients who are successfully and completely revascularized
at 6 months, 1 in 4 will have an event at 5 years and this event
will be due to disease progression in 40% to 50%. In those who
have not had an event, 1 in 4 will have clinically significant
inducible ischemia (silent in the majority) and again this will be
from disease progression in 40% to 50%. These findings
underscore the importance of aggressive secondary prevention,
lifestyle modification, and long-term surveillance for inducible
ischemia in all patients with CAD. The fact that the majority
of late events and new perfusion defects are target-vessel–
related should prompt us to consider CABG for proximal
diffuse disease of the left anterior descending artery. Paradox-
ically left main disease without much proximal and mid-left
anterior descending disease may be a PCI target.
Reprint requests and correspondence: Dr. Antonio Colombo,
EMO-GVM Centro Cuore Columbus, Via Buonarroti 48, 20145
Milan, Italy. E-mail: info@emocolumbus.it.
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